Date: 2016-04-07
Type of information: Licensing agreement
Compound: novel point-of-care thawing system for cell-based therapies
Company: Asymptote (UK) Asymptote (UK)
Therapeutic area: Technology - Services
Type agreement: licensing
Action mechanism:
Disease:
Details: • On April 7, 2016, the Cell and Gene Therapy Catapult, the UK organisation dedicated to the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, and Asymptote. a leading specialist in cryopreservation, announced a licencing agreement for a novel point-of-care thawing system for cell-based therapies that they developed in collaboration. The Cell and Gene Therapy Catapult will licence all foreground IP generated by this collaboration to Asymptote. As a result, Asymptote will be able to commercialise the product to the wider international cell therapy market. A family of vial and bag thawing devices have been developed over the last 12 months by both the Cell and Gene Therapy Catapult and Asymptote. They have been designed to optimise the thawing process and simplify the delivery of cell therapies to patients to address the significant challenges of delivery at the point-of-care. Asymptote is now preparing for commercial launch of the new devices with the first in the family expected to be on the market before the end of the year.
Financial terms:
Latest news:
